ABIOMED, Inc. (NASDAQ:ABMD) Files An 8-K Results of Operations and Financial Condition

Item2.02

On May4, 2017, we issued a press release reporting our financial
results for our fourth quarter and year ended March31, 2017. A
copy of the press release is set forth as Exhibit 99.1 and is
incorporated herein by reference. The information contained in
this report shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934 or otherwise subject to
the liabilities of that Section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933 or the Securities Act of 1934, whether made before or
after the date hereof and regardless of any general incorporation
language in such filing, except as expressly set forth by
specific reference in such filing.

About ABIOMED, Inc. (NASDAQ:ABMD)

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

ABIOMED, Inc. (NASDAQ:ABMD) Recent Trading Information

ABIOMED, Inc. (NASDAQ:ABMD) closed its last trading session down -4.39 at 129.89 with 552,012 shares trading hands.